vaccines targeting emerging variants of COVID-19 amid concerns that some mutations are making the virus harder to combat. Tam warns of coronavirus variants as new cases emerge across Canada GSK plans to invest 150 million euros ($181 million) to support the research of the Tubingen, Germany-based CureVac, which is developing vaccines that use messenger RNA to attack the disease.